
Disease risks
The complex interactions between the microbiome and its host create more than just differential disease risk. They also create differential metabolic phenotypes (Holmes et al., 2008a). In fact, disease risks and metabolic phenotypes are related both biologically and statistically, so disease risk can be assessed by measuring metabolite levels. Metabolite analysis falls under the scope of “metabonomics,” that is, “the quantitative measurement of multiparametric (time-dependent) metabolic responses of complex systems to a pathophysiological stimulus or genetic modification” (Nicholson et al.). al., 1999).
The complexity of the information obtained from extended metabolic profiles stems from the fact that not only do all human cells produce metabolites (with over 500 functionally distinct cell types), but so do all microbial cells (Nicholson et al., 2005). Microbes produce short-chain fatty acids, bile acids and related oxysterols, vasoactive (aromatic) amines, cresols and aromatic acids, endocannabinoids and other molecules.
Many microbial metabolites are involved in human metabolism. For example, bile acids, which are critical host signaling molecules, are co-metabolized by microbes, which has a significant impact on the risk of liver and colon diseases (Nicholson and Wilson, 2003). Bile acids are synthesized in the liver daily and then secreted into the mammalian intestine, where they are deconjugated into bile acid by Lactobacillus and other gut microbiota. Cholic acid, in turn, can be dehydroxylated by other microbes to deoxycholic acid. Deoxycholic acid is both hepatotoxic and carcinogenic. Microbial cometabolism of bile acids also influences lipid bioavailability.
When thinking about how the gut microbiome influences human metabolism, it is common to think about the processing of the distal colon and the production of short-chain fatty acids, but the microbiome also plays an important role in the upper gut, for example through lipid bioavailability.
Another body of evidence that the microbiome plays a key role in human metabolism comes from bariatric surgery studies in both animals and humans. Roux-en-Y gastric bypass (RYGB), the gold standard of bariatric surgery, is associated with an 80% reduction in the incidence of diabetes within 24 hours of surgery. This procedure is also associated with a reduced risk of colon and other cancers. Since diabetes is cured immediately (that is, and not after subsequent weight loss), there must be a biochemical explanation for this. Part of the explanation likely lies in the microbiome. Zhang et al (2009) reported a significant increase in Gammaproteobacteria in RYGB patients compared with normal and obese individuals. Using a rat model, Li et al. (2011b) also reported an increase in the abundance of Gammaproteobacteria as well as massive changes in bile acid metabolism after RYGB. Although changes in the microbiome may not be the “key” to understanding the connection between bariatric surgery and changes in the body’s risk of diabetes, cancer or other diseases, “they are certainly part of the gearbox” (Holmes et al., 2011).
Recommended Products

Contacts
Head office of the company
BIODONATUM TRADING
Dubai, United Arab Emirates, Dubai Silicon Oasis, DDP, Building A1





